Optimer files antibiotic fidaxomicin with FDA for C.difficile treatment
This article was originally published in Scrip
Executive Summary
Optimer Pharmaceuticals has filed an NDA with the US FDA for its narrow-spectrum antibiotic fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI.